Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

J&J Forges Ahead In Immunology Despite Competitive Dynamics

Executive Summary

The diversified pharma has two NMEs and three sNDAs pending at FDA in immunology, as well as six more anticipated sNDA filings. Immunology Therapeutic Head Susan Dillon told investors why there is still plenty of opportunity for growth in key autoimmune diseases.

Advertisement

Related Content

Sanofi/Regeneron's Kevzara Priced To Break Into A Crowded Market
J&J Plots Five-Year Pharma Growth Plan Around Mega-Brands And Launches
Pfizer Will Support Inflectra Launch With Dedicated Sales Force
Clever Marketing Needed To Position J&J's New Psoriasis Drug Ahead Of Cheaper Options

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel